

Based on the detailed PDF report provided for **LUPIN.NS** (dated 2026-01-31), here is the analysis from the perspective of a Positional Equity Trader.

Step 1: Audit the Data

- * **Data Present:**
 - * **Price Structure:** Daily, Weekly, and 15-min candlestick charts with moving averages (EMA 20, 50, 200).
 - * **Trend Indicators:** Supertrend, MACD, and EMA crossover status.
 - * **Volatility:** Bollinger Bands and Volatility Squeeze analysis.
 - * **Momentum/Strength:** RSI (Relative Strength Index) and Comparative Relative Strength (RS) against the Pharma sector.
 - * **Volume:** Distribution day analysis and Volume moving averages.
 - * **Fundamentals:** Snapshot of revenue/net income growth and valuation metrics.
- * **Data Missing:**
 - * **Fibonacci Retracements:** Specific retracement levels from the recent swing low/high are not explicitly drawn.
 - * **Order Book/Market Depth:** Real-time buying/selling pressure is not visible (standard for static reports).
 - * **Confidence Level:** **High.** The report provides a comprehensive technical and fundamental picture, allowing for a robust evidenced-based decision.
 - * **Note:** The report date is futuristic (2026). I am treating the data as "current" relative to the context of the analysis.

Step 2: Analyze the Setup

- * **Trend & Structure:**
 - * **Primary Trend:** **Bullish**. The stock is trading well above the 200 EMA (2027.24) and the Supertrend is positive (Green).
 - * **Intermediate Trend:** **Consolidation/Pullback.** The stock recently pulled back from highs (~2400) and found support at the **50 EMA (2113)**. It is currently sandwiching between the 50 EMA support and the 20 EMA resistance (2148).
 - * **Momentum:**
 - * **MACD:** **Bearish**. The MACD line is below the signal line (Page 13), indicating the immediate momentum is still negative/corrective. However, the histogram suggests the bearish momentum is fading (bars getting lighter/smaller).
 - * **RSI:** **Neutral (52.70).** It is not overbought, leaving room for upside, but lacks the "thrust" usually seen in breakout setups (>60).
 - * **Volume & Supply:**
 - * **Concern:** Page 18 highlights **5 Distribution Days** in late January 2026. This indicates institutional selling or profit-taking during the recent consolidation. This is the primary risk factor preventing an immediate aggressive entry.
 - * **Confluence:**
 - * **Support:** Strong confluence of support at the **2100-2115** level (50 EMA + Supertrend Value of 2089).
 - * **Fundamentals:** Net Income is up 57.80% (Quarter-over-Quarter), validating the long-term bullish thesis.

Step 3: Formulate the Recommendation

Verdict: **NO** (Do not enter *immediately* at market price).

Reasoning: While the long-term trend is up, the short-term setup is messy. The stock is currently fighting overhead resistance at the **Middle Bollinger Band (SMA 20) around 2160** and shows recent signs of distribution (selling volume). Entering exactly at 2152.80 puts you directly into resistance with bearish MACD momentum.

****Strategy:**** You need the price to prove that the "Distribution" phase is over and buyers have regained control of the 20-day average.

Conditional Trading Plan (Watchlist):

* ****Condition to Buy:**** Wait for a ****Daily Close above INR 2175****.

* ***Why:** This clears the Middle Bollinger Band (2160) and confirms the reclamation of the 20 EMA, shifting short-term momentum back to bullish.

* ****Entry Price:**** ****INR 2175 - INR 2185**** (On confirmation).

* ****Stop Loss:**** ****INR 2085**** (Hard Stop).

* ***Why:** This is just below the Supertrend support (2089) and the 50 EMA (2113). If this level breaks, the intermediate trend is violated.

* ****Take Profit:**** ****INR 2350**** (Target 1) / ****INR 2400**** (Target 2).

* ***Why:** INR 2350 is the recent resistance zone before the previous peak.

* ***Risk/Reward:** Risk is ~90 points; Reward is ~175 points (Approx 1:2 ratio).

****Summary:**** Good fundamental stock in a strong primary uptrend, but currently digesting gains. Wait for the trigger (2175+) to avoid "catching a falling knife" or getting stuck in sideways chop.

News & Analyst Targets

Based on the latest available information as of ****January 31, 2026****, here is the research update on Lupin Limited (LUPIN).

1) Latest News for LUPIN (Week of Jan 26 - Jan 31, 2026)

* ****Rating Adjustment:**** On January 28, 2026, ****MarketsMOJO**** downgraded Lupin's investment rating from "Strong Buy" to ****"Buy"**. The firm cited mixed technical signals as the primary reason, noting that while fundamentals (quality, valuation, financial trend) remain robust, the technical grade has shifted from bullish to "mildly bullish."**

* ****Upcoming Q3 Earnings:**** Lupin has scheduled a Board of Directors meeting for ****February 12, 2026****, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26).

* ****ESOP Allotment:**** On January 27, 2026, the company announced the allotment of ****169,140 equity shares**** to employees under its stock option plans.

* ****ESG Recognition:**** Earlier in the week (Jan 23), Lupin received the highest ****ESG rating**** from the CDP (formerly Carbon Disclosure Project) for its performance in Climate Change and Water Security, underscoring its leadership in sustainability.

* ****Semaglutide Deal:**** On January 21, 2026, Lupin signed a license and supply agreement with ****Galenicum**** to commercialize Semaglutide (a GLP-1 receptor agonist used for diabetes and weight loss) in 23 countries, expanding its footprint in the growing metabolic market.

2) Brokerage Upgrades & Downgrades

* ****MarketsMOJO:**** ****Downgrade**** to **BUY** (from Strong Buy) on Jan 28, 2026.

* ****Citi:**** Maintains **BUY** rating (Recent notes cite strong US growth and product pipeline).

* ****Consensus View:**** The broader analyst community retains an ****"Outperform" or "Buy" sentiment** on the stock, with recent breakouts in share price signaling potential bullish momentum despite the minor technical downgrade by MarketsMOJO.

3) Other News Impacting LUPIN

* ****US FDA Observations (Goa Facility):**** In late 2025 (November), the US FDA conducted an inspection of Lupin's Goa manufacturing facility which concluded with a ****Form-483 citing seven observations****. The company is currently in the process of addressing these findings. This remains a key monitorable for investors.

* ****Acquisition Timeline Update:**** Lupin has updated the completion timeline for its ****~190 million acquisition of VISUfarma B.V.**** (Netherlands) to ****February 28, 2026****. This move is set to strengthen its ophthalmology presence in Europe.

* **Technical Breakout:** Market experts have noted that Lupin recently broke out of a 7-month consolidation phase, suggesting a potential "bull comeback" with short-term trading targets around INR 2,290.

4) Latest Analyst Targets & Ratings

As of January 31, 2026

Brokerage / Source	Rating / Action	Target Price (INR)	Upside/Downside Potential	Notes
Consensus Mean	Outperform	2,306	~7.1%	Average of 19 reports
Trendlyne Consensus	Buy	2,347	~9.0%	Based on analyst aggregate
Technical Analysts	Buy (Short-Term)	2,290	~6.4%	Momentum-based target
Nomura / Instinet	Buy	2,350	~9.2%	Maintained Buy, adjusted PT
Citi	Buy	2,260	~5.0%	Upgraded from Sell (Prev Cycle)
UBS	Sell	2,050	~4.7%	Maintained cautious stance
High Estimate	--	2,600	~20.8%	Street High Target
Low Estimate	--	1,903	~11.6%	Street Low Target

Note: Stock price reference taken at ~INR 2,152 (Jan 30, 2026 close).


Stock Detailed Analysis Report

LUPIN.NS

Current Price: ₹2152.80

Generated: 2026-01-31 11:36

LUPIN.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

LUPIN.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	54.7/100
:	

== RS RATIOS ==:

1M RS:	1.061 [Leader]
3M RS:	1.134 [Leader]
6M RS:	1.132 [Leader]
1Y RS:	1.023 [Leader]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✗ Medium-term Lagging:	Not lagging
✓ Performance Improving:	3M (+10.1%) > 6M (+9.8%)

Relative Strength Analysis: LUPIN.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)




RS Composite Score Timeline



LUPIN.NS - EMA Crossover Summary

EMA 20:	2148.02
EMA 50:	2113.17
EMA 200:	2027.24
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-13 00:00:00+05:30
Golden Cross Price:	2052.90


LUPIN.NS EMA Crossover Analysis



LUPIN.NS - Bollinger Bands Summary

Current Price:	2152.80
Upper Band:	2226.40
Middle Band (SMA 20):	2160.73
Lower Band:	2095.06
%B:	0.4396
Band Width:	0.0608
Status:	Lower Half
Signal:	None
Recent Signal 1:	Sell Signal at 2025-11-17 00:00:00+05:30


LUPIN.NS Bollinger Bands (20, 2) Analysis



LUPIN.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	2089.93
Signal Identified On:	2025-11-12


Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




LUPIN.NS - MACD Summary

MACD Line:	8.72
Signal Line:	16.17
Histogram:	-7.45
Trend:	Bearish
Momentum:	Weakening
Signal:	None

LUPIN.NS Price






LUPIN.NS MACD (12, 26, 9)



LUPIN.NS - Volatility Squeeze Summary

BB Width:	0.0608
ATR:	45.7214
Total Signals:	32
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze (Bullish Breakout) at 2026-01-06 00:00:00+05




LUPIN.NS - Volatility Squeeze Analysis



LUPIN.NS - RSI-Volume Summary

Current RSI:	52.70
Current Volume:	1149131
Volume MA 20:	826387
Bullish Divergences:	0
Bearish Divergences:	3
Bearish Div 1:	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
Bearish Div 2:	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

LUPIN.NS RSI-Volume Divergence Analysis



LUPIN.NS - Volume Analysis



== VOLUME ANALYSIS ==:

Status: 38 Signals Detected

:

2026-01-16 [-]:	Distribution Day
2026-01-19 [-]:	Distribution Day
2026-01-20 [-]:	Distribution Day
2026-01-21 [-]:	Distribution Day
2026-01-28 [-]:	Distribution Day

LUPIN.NS - Volume Analysis




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	2025.98	2152.8	2025-12-01
1 Day	UPTREND (Buy)	2089.93	2152.8	2025-11-12
15 Min	DOWNTREND (Sell)	2157.19	2152.8	2026-01-30

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Weakening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bullish	Strengthening	No Signal

LUPIN.NS - 1 Week (Candlestick + EMAs)



LUPIN.NS - 1 Day (Candlestick + EMAs)



LUPIN.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - LUPIN_main

MarketsSTARFOLIOAlertsF&O MF Reports ScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

India

Login / Sign up

MARKETS / SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY : PHARMACEUTICALS / LUPIN LTD.

Lupin Ltd.

NSE: LUPIN | BSE: 500257

Lupin Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive

In 1 Starfolio Basket

2152.8020.70 (0.97%)

1.2M NSE+BSE Volume

NSE 30 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Lupin Key Metrics

Preset Metrics

My Metrics

Market Capitalization > High in industry	98,376	PE TTM > Above industry Median	22.7	PEG TTM > Below industry Median	0.4	Price to Book > Above industry Median
Institutional holding current Qtr % > High in industry	47.1	Revenue Growth Qtr YoY % > Below industry Median	24.2	Operating Revenue growth TTM % > Above industry Median	15.5	Net Profit Qtr Growth YoY % > Below industry Median
Net Profit TTM Growth % > Above industry Median	64.7	Operating Profit Margin Qtr % > High in industry	33.2	Operating Profit Margin TTM % > High in industry	27.3	Piotroski Score > Above industry Median
Rel Perf vs Nifty50 quarter% >	12.8	Rel Perf vs Sector quarter% >	15	ROE Annual % > High in industry	19.1	

All financials are in INR Cr and price data in INR

Durability & Valuation Scores

Free SIGN IN to see details

Momentum Score

60.7 / 100

Technically Moderately Bullish

FORECASTER

Please SUBSCRIBE to view forecasts

Strong Performer, Getting Expensive

These stocks are strong in quality and technicals but have medium valuation. At somewhat expensive v...

View Similar

Embed DVM

Key Metrics

DVM

Price Chart

Forecaster

Financials

Technicals

Shareholding


Deals

Documents

Corporate actions

Company Profile

Trendlyne Snapshot - LUPIN_forecaster



Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2306, revenue growth forecast of 14.8%, and profit growth estimate of 37.7% for FY26, based on top 37 analyst calls.



Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

Upgrade Now

Sign in

SAMPLE DATA BELOW

